In most cases, successful priming of antitumor T cell responses requires migration of tumor‐infiltrating DC (TIDC) to regional lymph nodes, where they are able to cross‐present Ag from phagocytosed tumor cells to naïve CD8+ T lymphocytes. This evidence concerns the gene CD8A and neoplasm.